Intraoperative imaging in ovarian cancer: Fact or fiction?

Molecular Imaging

Volumn 10, Issue 4, 2011, Pages 248-257

  Crane, Lucia M A ^a,b   Van Oosten, Marleen ^a,b   Pleijhuis, Rick G ^a,b   Motekallemi, Arash ^a,b   Dowdy, Sean C ^a,b   Cliby, William A ^a,b   Van Der Zee, Ate G J ^a,b   Van Dam, Gooitzen M ^a,b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL MODEL; BENEFICIAL EFFECTS; CANCER DIAGNOSIS; CHEMOKINE RECEPTORS; EPIDERMAL GROWTH FACTOR RECEPTORS; FLUORESCENCE IMAGING; FOLATE RECEPTOR; FOOD AND DRUG ADMINISTRATION; HUMAN USE; INTRA-OPERATIVE; MATRIX METALLOPROTEINASES; OVARIAN CANCERS; TARGET FINDING; VASCULAR ENDOTHELIAL GROWTH FACTOR;

DIAGNOSIS; FLUORESCENCE; PEPTIDES; SUBSTRATES; TUMORS;

DISEASES;

CHEMOKINE RECEPTOR CXCR4; CXCR4 PROTEIN, HUMAN; EPIDERMAL GROWTH FACTOR RECEPTOR; FOLATE RECEPTOR 1; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A;

ANIMAL; DIAGNOSTIC IMAGING; FEMALE; HUMAN; INTRAOPERATIVE PERIOD; MEDLINE; METABOLISM; METHODOLOGY; OVARY TUMOR; PATHOLOGY; REVIEW; UTILIZATION REVIEW;

ANIMALS; CHEMOKINE CXCL12; DIAGNOSTIC IMAGING; FEMALE; FOLATE RECEPTOR 1; HUMANS; INTRAOPERATIVE PERIOD; OVARIAN NEOPLASMS; PUBMED; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, CXCR4; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79959752763     PISSN: 15353508     EISSN: None     Source Type: Journal    
DOI: 10.2310/7290.2011.00004     Document Type: Article

References (127)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96, doi:10.3322/CA.2007.0010. (Pubitemid 351521864)
2. Winter WE III, Maxwell GL, Tian C, et al. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 2008;26:83-9, doi:10.1200/JCO.2007.13.1953.
3. Zivanovic O, Aldini A, Carlson JW, et al. Advanced cytoreductive surgery: American perspective. Gynecol Oncol 2009;114(2 Suppl):S3-9, doi:10.1016/j.ygyno.2008.11.033.
4. Aletti GD, Dowdy SC, Gostout BS, et al. Aggressive surgical effort and improved survival in advanced-stage ovarian cancer. Obstet Gynecol 2006;107:77-85.
5. Vergote I, van Gorp T, Amant F, et al. Timing of debulking surgery in advanced ovarian cancer. Int J Gynecol Cancer 2008;18 Suppl 1:11-9, doi:10.1111/j.1525-1438.2007.01098.x. (Pubitemid 351389047)
6. Wimberger P, Wehling M, Lehmann N, et al. Influence of residual tumor on outcome in ovarian cancer patients with FIGO stage IV disease: an exploratory analysis of the AGO-OVAR (Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group). Ann Surg Oncol 2010;17:1642-8, doi:10.1245/s10434-010-0964- 9.
7. Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol 2002;20: 1248-59, doi:10.1200/JCO.20.5.1248. (Pubitemid 34177431)
8. Tian WJ, Jiang R, Cheng X, et al. Surgery in recurrent epithelial ovarian cancer: benefits on survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J Surg Oncol 2010;101:244-50.
9. Chi DS, Eisenhauer EL, Zivanovic O, et al. Improved progressionfree and overall survival in advanced ovarian cancer as a result of a change in surgical paradigm. Gynecol Oncol 2009;114:26-31, doi:10.1016/j.ygyno.2009.03.018.
10. Los G, Mutsaers PH, Lenglet WJ, et al. Platinum distribution in intraperitoneal tumors after intraperitoneal cisplatin treatment. Cancer Chemother Pharmacol 1990;25:389-94, doi:10.1007/BF00686048. (Pubitemid 20069336)
11. Los G, Mutsaers PH, van der Vijgh WJ, et al. Direct diffusion of cis-diamminedichloroplatinum(II) in intraperitoneal rat tumors after intraperitoneal chemotherapy: a comparison with systemic chemotherapy. Cancer Res 1989;49:3380-4. (Pubitemid 19162154)
12. Howell SB. Pharmacologic principles of intraperitoneal chemotherapy for the treatment of ovarian cancer. Int J Gynecol Cancer 2008; 18 Suppl 1:20-5, doi:10.1111/j.1525-1438.2007.01099.x. (Pubitemid 351389048)
13. de Bree E, Rosing H, Michalakis J, et al. Intraperitoneal chemotherapy with taxanes for ovarian cancer with peritoneal dissemination. Eur J Surg Oncol 2006;32:666-70, doi:10.1016/j.ejso.2006.03.008. (Pubitemid 44087882)
14. Forstner R. Radiological staging of ovarian cancer: imaging findings and contribution of CT and MRI. Eur Radiol 2007;17: 3223-35, doi:10.1007/s00330-007- 0736-5. (Pubitemid 350142347)
15. Musto A, Rampin L, Nanni C, et al. Present and future of PET and PET/CT in gynaecologic malignancies. Eur J Radiol. 2010 Jan 28. [Epub ahead of print], doi:10.1016/j.ejrad.2009.12.035
16. Nam EJ, Yun MJ, Oh YT, et al. Diagnosis and staging of primary ovarian cancer: correlation between PET/CT, Doppler US, and CT or MRI. Gynecol Oncol 2010;116:389-94, doi:10.1016/j.ygyno.2009.10.059.
17. Tempany CM, Zou KH, Silverman SG, et al. Staging of advanced ovarian cancer: comparison of imaging modalities-report from the Radiological Diagnostic Oncology Group. Radiology 2000; 215:761-7. (Pubitemid 30346013)
18. Low RN, Sebrechts CP, Barone RM, et al. Diffusion-weighted MRI of peritoneal tumors: comparison with conventional MRI and surgical and histopathologic findings-a feasibility study. AJR Am J Roentgenol 2009;193:461-70, doi:10.2214/AJR.08.1753.
19. Kyriazi S, Collins DJ, Morgan VA, et al. Diffusion-weighted imaging of peritoneal disease for noninvasive staging of advanced ovarian cancer. Radiographics 2010;30:1269-85, doi:10.1148/rg.305105073.
20. Funicelli L, Travaini LL, Landoni F, et al. Peritoneal carcinomatosis from ovarian cancer: the role of CT and [(18)F]FDG-PET/ CT. Abdom Imaging. 2009 Sep 26. [Epub ahead of print], doi:10.1007/s00261-009-9578-8.
21. Cho JE, Liu C, Gossner G, et al. Laparoscopy and gynecologic oncology. Clin Obstet Gynecol 2009;52:313-26, doi:10.1097/GRF.0b013e3181b088d2.
22. De Iaco P, Musto A, Orazi L, et al. FDG-PET/CT in advanced ovarian cancer staging: value and pitfalls in detecting lesions in different abdominal and pelvic quadrants compared with laparoscopy. Eur J Radiol. 2010 Aug 3. [Epub ahead of print], doi:10.1016/j.ejrad.2010.07.013.
23. Benedet JL, Bender H, Jones H III, et al. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000;70:209-62, doi:10.1016/S0020-7292(00)90001-8.
24. Aebi S, Castiglione M. Newly and relapsed epithelial ovarian carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20 Suppl 4:21-3.
25. Hama Y, Urano Y, Koyama Y, et al. In vivo spectral fluorescence imaging of submillimeter peritoneal cancer implants using a lectin-targeted optical agent. Neoplasia 2006;8:607-12, doi:10.1593/neo.06268. (Pubitemid 44061316)
26. Troy T, Jekic-McMullen D, Sambucetti L, et al. Quantitative comparison of the sensitivity of detection of fluorescent and bioluminescent reporters in animal models. Mol Imaging 2004;3: 9-23, doi:10.1162/153535004773861688.
27. Sevick-Muraca EM, Lopez G, Reynolds JS, et al. Fluorescence and absorption contrast mechanisms for biomedical optical imaging using frequency-domain techniques. Photochem Photobiol 1997;66:55-64, doi:10.1111/j.1751-1097.1997.tb03138.x. (Pubitemid 127470633)
28. Mordon S, Devoisselle JM, Soulie-Begu S, et al. Indocyanine green: physicochemical factors affecting its fluorescence in vivo. Microvasc Res 1998;55:146-52, doi:10.1006/mvre.1998.2068. (Pubitemid 28368700)
29. Alford R, Simpson HM, Duberman J, et al. Toxicity of organic fluorophores used in molecular imaging: literature review. Mol Imaging 2009;8:341-54.
30. Butner RW, McPherson AR. Adverse reactions in intravenous fluorescein angiography. Ann Ophthalmol 1983;15:1084-6. (Pubitemid 14232328)
31. Kovar JL, Simpson MA, Schutz-Geschwender A, et al. A systematic approach to the development of fluorescent contrast agents for optical imaging of mouse cancer models. Anal Biochem 2007;367:1-12, doi:10.1016/j.ab.2007.04.011. (Pubitemid 46938663)
32. Themelis G, Yoo JS, Soh KS, et al. Real-time intraoperative fluorescence imaging system using light-absorption correction. J Biomed Opt 2009;14:064012, doi:10.1117/1.3259362.
33. Troyan SL, Kianzad V, Gibbs-Strauss SL, et al. The FLARE intraoperative near-infrared fluorescence imaging system: a firstin-human clinical trial in breast cancer sentinel lymph node mapping. Ann Surg Oncol 2009;16:2943-52, doi:10.1245/s10434-009-0594-2.
34. Fujiwara M, Mizukami T, Suzuki A, et al. Sentinel lymph node detection in skin cancer patients using real-time fluorescence navigation with indocyanine green: preliminary experience. J Plast Reconstr Aesthet Surg 2009;62:e373-8, doi:10.1016/j.bjps.2007.12.074.
35. Ishizawa T, Bandai Y, Ijichi M, et al. Fluorescent cholangiography illuminating the biliary tree during laparoscopic cholecystectomy. Br J Surg 2010;97:1369-77, doi:10.1002/bjs.7125.
36. Parungo CP, Ohnishi S, Kim SW, et al. Intraoperative identification of esophageal sentinel lymph nodes with near-infrared fluorescence imaging. J Thorac Cardiovasc Surg 2005;129:844-50, doi:10.1016/j.jtcvs.2004.08.001. (Pubitemid 40487887)
37. Low PS, Kularatne SA. Folate-targeted therapeutic and imaging agents for cancer. Curr Opin Chem Biol 2009;13:256-62, doi:10.1016/j.cbpa.2009.03.022.
38. Yamaguchi T, Hirota K, Nagahama K, et al. Control of immune responses by antigen-specific regulatory T cells expressing the folate receptor. Immunity 2007;27:145-59, doi:10.1016/j.immuni. 2007.04.017. (Pubitemid 47089022)
39. Parker N, Turk MJ, Westrick E, et al. Folate receptor expression in carcinomas and normal tissues determined by a quantitative radioligand binding assay. Anal Biochem 2005;338:284-93, doi:10.1016/j.ab.2004.12.026. (Pubitemid 40312593)
40. Kalli KR, Oberg AL, Keeney GL, et al. Folate receptor alpha as a tumor target in epithelial ovarian cancer. Gynecol Oncol 2008; 108:619-26, doi:10.1016/j.ygyno.2007.11.020.
41. Markert S, Lassmann S, Gabriel B, et al. Alpha-folate receptor expression in epithelial ovarian carcinoma and non-neoplastic ovarian tissue. Anticancer Res 2008;28:3567-72.
42. Low PS, Antony AC. Folate receptor-targeted drugs for cancer and inflammatory diseases. Adv Drug Deliv Rev 2004;56:1055-8, doi:10.1016/j.addr. 2004.02.003. (Pubitemid 38496506)
43. Leamon CP, Low PS. Delivery of macromolecules into living cells: a method that exploits folate receptor endocytosis. Proc Natl Acad Sci U S A 1991;88:5572-6, doi:10.1073/pnas.88.13.5572. (Pubitemid 21914787)
44. Low PS, Henne WA, Doorneweerd DD. Discovery and development of folic-acid-based receptor targeting for imaging and therapy of cancer and inflammatory diseases. Acc Chem Res 2008 ;41:120-9, doi:10.1021/ar7000815.
45. Jackman AL, Theti DS, Gibbs DD. Antifolates targeted specifically to the folate receptor. Adv Drug Deliv Rev 2004;56:1111-25, doi:10.1016/j.addr.2004.01. 003. (Pubitemid 38496511)
46. Reddy JA, Dorton R, Westrick E, et al. Preclinical evaluation of EC145, a folate-vinca alkaloid conjugate. Cancer Res 2007;67: 4434-42, doi:10.1158/0008-5472.CAN-07-0033. (Pubitemid 46815093)
47. Lu Y, Low PS. Folate targeting of haptens to cancer cell surfaces mediates immunotherapy of syngeneic murine tumors. Cancer Immunol Immunother 2002;51:153-62, doi:10.1007/s00262-002-0266-6. (Pubitemid 34298111)
48. Lu Y, Sega E, Low PS. Folate receptor-targeted immunotherapy: induction of humoral and cellular immunity against haptendecorated cancer cells. Int J Cancer 2005;116:710-9, doi:10.1002/ijc.21126. (Pubitemid 41099702)
49. Mathias CJ, Wang S, Waters DJ, et al. Indium-111-DTPAfolate as a potential folate-receptor-targeted radiopharmaceutical. J Nucl Med 1998;39:1579-85.
50. Siegel BA, Dehdashti F, Mutch DG, et al. Evaluation of 111In- DTPA-folate as a receptor-targeted diagnostic agent for ovarian cancer: initial clinical results. J Nucl Med 2003;44:700-7. (Pubitemid 39655203)
51. Leamon CP, Parker MA, Vlahov IR, et al. Synthesis and biological evaluation of EC20: a new folate-derived, (99m)Tc-based radiopharmaceutical. Bioconjug Chem 2002;13:1200-10, doi:10.1021/bc0200430. (Pubitemid 35420011)
52. Fisher RE, Siegel BA, Edell SL, et al. Exploratory study of 99mTc-EC20 imaging for identifying patients with folate receptorpositive solid tumors. J Nucl Med 2008;49:899-906, doi:10.2967/jnumed.107.049478. (Pubitemid 351793430)
53. Ebel W, Routhier EL, Foley B, et al. Preclinical evaluation of MORAb-003, a humanized monoclonal antibody antagonizing folate receptor-alpha. Cancer Immun 2007;7:6.
54. Spannuth WA, Sood AK, Coleman RL. Farletuzumab in epithelial ovarian carcinoma. Expert Opin Biol Ther 2010;10:431-7, doi:10.1517/14712591003592069.
55. Armstrong DK, Bicher A, Coleman RL, et al. Exploratory phase II efficacy study of MORAb-003, a monoclonal antibody against folate receptor alpha, in platinum-sensitive ovarian cancer in first relapse [abstract[. J Clin Oncol 2008;26:5500, doi:10.1200/JCO.2008.18.6064.
56. Smith-Jones PM, Pandit-Taskar N, Cao W, et al. Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003. Nucl Med Biol 2008;35:343-51, doi:10.1016/j.nucmedbio. 2007.12.008. (Pubitemid 351381971)
57. Kennedy MD, Jallad KN, Thompson DH, et al. Optical imaging of metastatic tumors using a folate-targeted fluorescent probe. J Biomed Opt 2003;8:636-41, doi:10.1117/1.1609453.
58. Birner P, Schindl M, Obermair A, et al. Expression of hypoxiainducible factor 1alpha in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin Cancer Res 2001;7:1661-8. (Pubitemid 32708633)
59. Barnas C, Martel-Planche G, Furukawa Y, et al. Inactivation of the p53 protein in cell lines derived from human esophageal cancers. Int J Cancer 1997;71:79-87, doi:10.1002/(SICI)1097-0215 (19970328)71:1,〈79::AID- IJC14〉3.0.CO;2-4. (Pubitemid 27158413)
60. Hockel M, Schlenger K, Hockel S, et al. Hypoxic cervical cancers with low apoptotic index are highly aggressive. Cancer Res 1999; 59:4525-8. (Pubitemid 29428951)
61. Vaupel P, Harrison L. Tumor hypoxia: causative factors, compensatory mechanisms, and cellular response. Oncologist 2004;9 Suppl 5:4-9, doi:10.1634/theoncologist.9-90005-4. (Pubitemid 39658340)
62. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47, doi:10.1038/nrc704. (Pubitemid 37328806)
63. Maynard MA, Ohh M. The role of hypoxia-inducible factors in cancer. Cell Mol Life Sci 2007;64:2170-80, doi:10.1007/s00018-007-7082-2. (Pubitemid 350103108)
64. Bacon AL, Harris AL. Hypoxia-inducible factors and hypoxic cell death in tumour physiology. Ann Med 2004;36:530-9, doi:10.1080/07853890410018231. (Pubitemid 39490962)
65. Greijer AE, van der Groep P, Kemming D, et al. Up-regulation of gene expression by hypoxia is mediated predominantly by hypoxia-inducible factor 1 (HIF-1). J Pathol 2005;206:291-304, doi:10.1002/path.1778. (Pubitemid 40903193)
66. Liu LZ, Hu XW, Xia C, et al. Reactive oxygen species regulate epidermal growth factor-induced vascular endothelial growth factor and hypoxia-inducible factor-1alpha expression through activation of AKT and P70S6K1 in human ovarian cancer cells. Free Radic Biol Med 2006;41:1521-33, doi:10.1016/j.freeradbiomed. 2006.08.003. (Pubitemid 44528250)
67. Kumaran GC, Jayson GC, Clamp AR. Antiangiogenic drugs in ovarian cancer. Br J Cancer 2009;100:1-7, doi:10.1038/sj.bjc. 6604767.
68. Zhong H, De Marzo AM, Laughner E, et al. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res 1999;59:5830-5.
69. Shimogai R, Kigawa J, Itamochi H, et al. Expression of hypoxiainducible factor 1alpha gene affects the outcome in patients with ovarian cancer. Int J Gynecol Cancer 2008;18:499-505, doi:10.1111/j.1525-1438.2007.01055.x. (Pubitemid 351668322)
70. Lee S, Garner EI, Welch WR, et al. Over-expression of hypoxiainducible factor 1 alpha in ovarian clear cell carcinoma. Gynecol Oncol 2007;106:311-7, doi:10.1016/j.ygyno.2007.03.041. (Pubitemid 47087928)
71. Kim KS, Sengupta S, Berk M, et al. Hypoxia enhances lysophosphatidic acid responsiveness in ovarian cancer cells and lysophosphatidic acid induces ovarian tumor metastasis in vivo. Cancer Res 2006;66:7983-90, doi:10.1158/0008-5472.CAN-05-4381. (Pubitemid 44299162)
72. Mor G, Visintin I, Lai Y, et al. Serum protein markers for early detection of ovarian cancer. Proc Natl Acad Sci U S A 2005;102: 7677-82, doi:10.1073/pnas.0502178102. (Pubitemid 40741030)
73. Voldborg BR, Damstrup L, Spang-Thomsen M, et al. Epidermal growth factor receptor (EGFR) and EGFR mutations, function and possible role in clinical trials. Ann Oncol 1997;8:1197-206, doi:10.1023/A:1008209720526. (Pubitemid 28164074)
74. Hefler LA, Mustea A, Konsgen D, et al. Vascular endothelial growth factor gene polymorphisms are associated with prognosis in ovarian cancer. Clin Cancer Res 2007;13:898-901, doi:10.1158/1078-0432.CCR-06-1008. (Pubitemid 46340365)
75. Trinh XB, Tjalma WA, Vermeulen PB, et al. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 2009;100:971-8, doi:10.1038/sj.bjc.6604921.
76. Collinson F, Jayson G. New therapeutic agents in ovarian cancer. Curr Opin Obstet Gynecol 2009;21:44-53, doi:10.1097/GCO.0b013e32831ffe71.
77. Sánchez-Muñoz A, Mendolia C, Rodriguez CA, et al. Bevacizumab plus low-dose metronomic oral cyclophosphamide in heavily pretreated recurrent ovarian cancer [abstract]. J Clin Oncol 2010;28 Suppl:abstr e15507.
78. Burger RA, Sill MW, Monk BJ, et al. Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group study. J Clin Oncol 2007;25:5165-71, doi:10.1200/JCO.2007.11.5345. (Pubitemid 350237599)
79. Tillmanns TD, Lowe MP, Schwartzberg LS, et al. A phase II study of bevacizumab with nab-paclitaxel in patients with recurrent, platinum-resistant primary epithelial ovarian or primary peritoneal carcinoma [abstract]. J Clin Oncol 2010;28 Suppl 15:abstr 5009.
80. Burger RA, Liang SX, Boente M, et al. Phase III trial of bevacizumab (BEV) in the primary treatment of advanced epithelial ovarian cancer (EOC), primary peritoneal cancer (PPC), or fallopian tube cancer (FTC): a Gynecologic Oncology Group study [abstract]. J Clin Oncol 2010;28 Suppl 18:abstr LBA1.
81. Nagengast WB, de Vries EG, Hospers GA, et al. In vivo VEGF imaging with radiolabeled bevacizumab in a human ovarian tumor xenograft. J Nucl Med 2007;48:1313-9, doi:10.2967/jnumed.107.041301. (Pubitemid 47242797)
82. Nagengast WB, Lub-de Hooge MN, van Straten EME, et al. VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients [thesis]. Groningen (the Netherlands): Rijksuniversiteit Groningen; 2009.
83. Backer MV, Levashova Z, Patel V, et al. Molecular imaging of VEGF receptors in angiogenic vasculature with single-chain VEGF-based probes. Nat Med 2007;13:504-9, doi:10.1038/nm1522. (Pubitemid 46559824)
84. Abu-Jawdeh GM, Faix JD, Niloff J, et al. Strong expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in ovarian borderline and malignant neoplasms. Lab Invest 1996;74:1105-15. (Pubitemid 26184421)
85. Bates DO, Harper SJ. Regulation of vascular permeability by vascular endothelial growth factors. Vascul Pharmacol 2002;39: 225-37, doi:10.1016/S1537-1891(03)00011-9. (Pubitemid 37490748)
86. Kobold S, Hegewisch-Becker S, Oechsle K, et al. Intraperitoneal VEGF inhibition using bevacizumab: a potential approach for the symptomatic treatment of malignant ascites? Oncologist 2009;14: 1242-51, doi:10.1634/theoncologist. 2009-0109.
87. Pasquet M, Golzio M, Mery E, et al. Hospicells (ascites-derived stromal cells) promote tumorigenicity and angiogenesis. Int J Cancer 2010;126:2090-101.
88. Giuntoli RL, Webb TJ, Zoso A, et al. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity. Anticancer Res 2009;29:2875-84.
89. Brustmann H. Epidermal growth factor receptor expression in serous ovarian carcinoma: an immunohistochemical study with galectin-3 and cyclin D1 and outcome. Int J Gynecol Pathol 2008; 27:380-9, doi:10.1097/PGP. 0b013e31815d060d.
90. Zeineldin R, Muller CY, Stack MS, et al. Targeting the EGF receptor for ovarian cancer therapy. J Oncol 2010:414676. Epub 2009 Dec 28, doi:10.1155/2010/414676.
91. Lafky JM, Wilken JA, Baron AT, et al. Clinical implications of the ErbB/epidermal growth factor (EGF) receptor family and its ligands in ovarian cancer. Biochim Biophys Acta 2008;1785: 232-65.
92. Skirnisdottir I, Sorbe B, Seidal T. The growth factor receptors HER-2/neu and EGFR, their relationship, and their effects on the prognosis in early stage (FIGO I-II) epithelial ovarian carcinoma. Int J Gynecol Cancer 2001;11:119-29, doi:10.1046/j.1525-1438.2001.011002119.x. (Pubitemid 32381660)
93. de Graeff P, Crijns AP, de Jong S, et al. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer 2009;101:149-59, doi:10.1038/sj.bjc. 6605112.
94. Xia W, Wei Y, Du Y, et al. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 2009;48:610-7, doi:10.1002/mc.20504.
95. Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995;19:183-232, doi:10.1016/1040-8428(94)00144-I.
96. Kim ES, Khuri FR, Herbst RS. Epidermal growth factor receptor biology (IMC-C225). Curr Opin Oncol 2001;13:506-13, doi:10.1097/00001622-200111000- 00014. (Pubitemid 33027904)
97. Ogawa M, Regino CA, Seidel J, et al. Dual-modality molecular imaging using antibodies labeled with activatable fluorescence and a radionuclide for specific and quantitative targeted cancer detection. Bioconjug Chem 2009;20:2177-84, doi:10.1021/bc900362k.
98. Ogawa M, Kosaka N, Choyke PL, et al. In vivo molecular imaging of cancer with a quenching near-infrared fluorescent probe using conjugates of monoclonal antibodies and indocyanine green. Cancer Res 2009;69:1268-72, doi:10.1158/0008-5472.CAN-08-3116.
99. Milenic DE, Wong KJ, Baidoo KE, et al. Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications. Cancer Biother Radiopharm 2008;23:619-31, doi:10.1089/cbr.2008.0493.
100. Nayak TK, Regino CA, Wong KJ, et al. PET imaging of HER1-expressing xenografts in mice with (86)Y-CHX-A"-DTPAcetuximab. Eur J Nucl Med Mol Imaging 2010;37:1368-76, doi:10.1007/s00259-009-1370-z.
101. Harding J, Burtness B. Cetuximab: an epidermal growth factor receptor chimeric human-murine monoclonal antibody. Drugs Today (Barc) 2005;41:107-27, doi:10.1358/dot.2005.41.2.882662. (Pubitemid 40461533)
102. Gort EH, Groot AJ, van der Wall E, et al. Hypoxic regulation of metastasis via hypoxia-inducible factors. Curr Mol Med 2008;8: 60-7, doi:10.2174/156652408783565568. (Pubitemid 351516825)
103. Balkwill F. The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol 2004;14:171-9, doi:10.1016/j.semcancer.2003. 10.003. (Pubitemid 38586742)
104. Arya M, Ahmed H, Silhi N, et al. Clinical importance and therapeutic implications of the pivotal CXCL12-CXCR4 (chemokine ligand-receptor) interaction in cancer cell migration. Tumour Biol 2007;28:123-31, doi:10.1159/000102979. (Pubitemid 46975998)
105. Barbieri F, Bajetto A, Florio T. Role of chemokine network in the development and progression of ovarian cancer: a potential novel pharmacological target. J Oncol 2010:426956. Epub 2009 Dec 14, doi:10.1155/2010/426956.
106. Kajiyama H, Shibata K, Terauchi M, et al. Involvement of SDF-1alpha/CXCR4 axis in the enhanced peritoneal metastasis of epithelial ovarian carcinoma. Int J Cancer 2008;122:91-9, doi:10.1002/ijc.23083. (Pubitemid 350209982)
107. Scotton CJ, Wilson JL, Milliken D, et al. Epithelial cancer cell migration: a role for chemokine receptors? Cancer Res 2001;61: 4961-5. (Pubitemid 32681518)
108. Scotton CJ, Wilson JL, Scott K, et al. Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer. Cancer Res 2002;62:5930-8. (Pubitemid 35204756)
109. Jiang YP, Wu XH, Shi B, et al. Expression of chemokine CXCL12 and its receptor CXCR4 in human epithelial ovarian cancer: an independent prognostic factor for tumor progression. Gynecol Oncol 2006;103:226-33, doi:10.1016/j.ygyno.2006.02.036. (Pubitemid 44374693)
110. Jiang YP, Wu XH, Xing HY, et al. Role of CXCL12 in metastasis of human ovarian cancer. Chin Med J (Engl) 2007;120:1251-5.
111. Nomura W, Tanabe Y, Tsutsumi H, et al. Fluorophore labeling enables imaging and evaluation of specific CXCR4-ligand interaction at the cell membrane for fluorescence-based screening. Bioconjug Chem 2008;19:1917-20, doi:10.1021/bc800216p.
112. Nimmagadda S, Pullambhatla M, Pomper MG. Immunoimaging of CXCR4 expression in brain tumor xenografts using SPECT/CT. J Nucl Med 2009;50:1124-30, doi:10.2967/jnumed.108.061325.
113. Zhang J, Tian J, Li T, et al. 99mTc-AMD3100: a novel potential receptor-targeting radiopharmaceutical for tumor imaging. Chin Chem Lett 2010;21:461-3, doi:10.1016/j.cclet.2009.12.018.
114. Torng PL, Mao TL, Chan WY, et al. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression. Gynecol Oncol 2004;92:559-67, doi:10.1016/j.ygyno.2003.11.011. (Pubitemid 38183145)
115. Roomi MW, Monterrey JC, Kalinovsky T, et al. In vitro modulation of MMP-2 and MMP-9 in human cervical and ovarian cancer cell lines by cytokines, inducers and inhibitors. Oncol Rep 2010;23:605-14.
116. Zohny SF, Fayed ST. Clinical utility of circulating matrix metalloproteinase-7 (MMP-7), CC chemokine ligand 18 (CCL18) and CC chemokine ligand 11 (CCL11) as markers for diagnosis of epithelial ovarian cancer. Med Oncol. 2009 Nov 24. [Epub ahead of print], doi:10.1007/s12032-009-9366-x.
117. Moss NM, Barbolina MV, Liu Y, et al. Ovarian cancer cell detachment and multicellular aggregate formation are regulated by membrane type 1 matrix metalloproteinase: a potential role in I.p. metastatic dissemination. Cancer Res 2009;69:7121-9, doi:10.1158/0008-5472.CAN-08-4151.
118. Kamat AA, Fletcher M, Gruman LM, et al. The clinical relevance of stromalmatrixmetalloproteinase expression in ovarian cancer. Clin Cancer Res 2006;12:1707-14, doi:10.1158/1078-0432.CCR-05-2338.
119. Naylor MS, Stamp GW, Davies BD, et al. Expression and activity of MMPS and their regulators in ovarian cancer. Int J Cancer 1994;58:50-6, doi:10.1002/ijc.2910580110. (Pubitemid 24213969)
120. Shen X, Wang S, Wang H, et al. The role of SDF-1/CXCR4 axis in ovarian cancer metastasis. J Huazhong Univ Sci Technolog Med Sci 2009;29:363-7, doi:10.1007/s11596-009-0320-0.
121. von Burstin J, Eser S, Seidler B, et al. Highly sensitive detection of early-stage pancreatic cancer by multimodal near-infrared molecular imaging in living mice. Int J Cancer 2008;123:2138-47, doi:10.1002/ijc.23780.
122. Olson ES, Aguilera TA, Jiang T, et al. In vivo characterization of activatable cell penetrating peptides for targeting protease activity in cancer. Integr Biol (Camb ) 2009;1:382-93, doi:10.1039/b904890a.
123. Aguilera TA, Olson ES, Timmers MM, et al. Systemic in vivo distribution of activatable cell penetrating peptides is superior to that of cell penetrating peptides. Integr Biol (Camb) 2009;1:371-81, doi:10.1039/b904878b.
124. Hockel M, Schlenger K, Aral B, et al. Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 1996;56:4509-15. (Pubitemid 26330463)
125. Ozbudak IH, Karaveli S, Simsek T, et al. Neoangiogenesis and expression of hypoxia-inducible factor 1alpha, vascular endothelial growth factor, and glucose transporter-1 in endometrioid type endometrium adenocarcinomas. Gynecol Oncol 2008;108:603-8, doi:10.1016/j.ygyno.2007.11.028.
126. Takahashi K, Saga Y, Mizukami H, et al. Cetuximab inhibits growth, peritoneal dissemination, and lymph node and lung metastasis of endometrial cancer, and prolongs host survival. Int J Oncol 2009;35:725-9.
127. Hricak H, Gatsonis C, Chi DS, et al. Role of imaging in pretreatment evaluation of early invasive cervical cancer: results of the intergroup study American College of Radiology Imaging Network 6651-Gynecologic Oncology Group 183. J Clin Oncol 2005;23:9329-37, doi:10.1200/JCO.2005.02.0354.